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ABSTRACT
Introduction: Treatment patterns, including 
persistence, gaps in therapy, switching, and 
discontinuation, were examined in patients 
with psoriatic arthritis (PsA) who received the 
tumor necrosis factor (TNF)-blockers etanercept 
or adalimumab.
Methods: This retrospective study utilized 
administrative claims data from a United 
States commercial health plan. Adults (age 
18–64 years) with PsA who started therapy with 
etanercept or adalimumab as index therapy 
between January 1, 2006 and December 31, 
2008 were included in the analysis. Patients 
were continuously enrolled in the health 
plan for at least 6 months before and at least 
12 months after the start of index therapy. 
Initial TNF-blocker dose and rates of therapy 
persistence (continuous use of index medication 
without a gap of at least 60 days), therapy gaps, 
and discontinuation (gap in therapy of at least 
60 days) were estimated. Those who discontinued 
were further classified as: (1) discontinued all 
biologic therapy, (2) restarted index medication, 
(3) switched to another biologic therapy, or 
(4) other.
Results: A total of 346 patients with PsA (202 
etanercept, 144 adalimumab) were eligible. Most 
(90.6% etanercept; 88.9% adalimumab) started 
index therapy at the labeled dose. Persistence 
with index therapy for 12 months was observed 
in 50% of patients on etanercept and 45% of 
patients on adalimumab (P = 0.37). Patients on 
etanercept had a longer duration of persistence 
(434 vs. 353 days; P = 0.02), more pauses of 
at least 7 days (4.7 vs. 3.5; P = 0.004), and a 
longer mean pause length (48.6 vs. 29.3 days; 
P = 0.01) than patients on adalimumab. Of 
patients who discontinued (24.8% etanercept; 
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According to the prescribing information for 
PsA, etanercept should be administered at 50 mg 
weekly and adalimumab should be administered 
at 40 mg every other week (EOW) [12,13].
Few studies have examined TNF-blocker 
treatment patterns in patients with PsA, 
and, to the authors’ knowledge, no studies 
have examined treatment gaps, restarts, and 
switching in this patient population. A better 
understanding of treatment patterns would be 
useful to inform clinical practice decisions to 
ensure full treatment benefits and understand 
reasons for noncompliance. Saad et al. observed 
that 75.5% of patients with PsA in the British 
Society for Rheumatology Biologics Register 
(BSRBR) were persistent on their initial TNF-
blocker for 12 months [14]. The objective of 
this study was to describe real-world treatment 
patterns of etanercept and adalimumab in 
terms of therapy persistence, pauses in therapy, 
therapy discontinuation, therapy restarts, 




This retrospective cohort study used administrative 
claims data from a large, national United States (US) 
commercial health plan affiliated with 
OptumInsightTM. The Life Sciences Research 
Database (formerly the Ingenix database) 
comprises fully adjudicated medical and pharmacy 
claims for over 27 million adults across the US.
Patients
Patients with a diagnosis of PsA who started 
therapy with etanercept or adalimumab as index 
therapy between January 1, 2006 and December 31, 
2008 were included in the analysis. To be eligible, 
35.1% adalimumab), 46.4% and 41.5% restarted 
etanercept and adalimumab, respectively; 
24.8% and 35.1% discontinued all TNF-blockers; 
20.0% and 19.2% switched to another biologic; 
and 8.8% and 4.3% had other therapy changes.
Conclusions: Approximately half of PsA patients 
were persistent on their index TNF-blocker for 
12 months. Pauses in therapy and therapy 
discontinuation were common, but more than 
40% of patients restarted their index TNF-
blocker after discontinuation.
Keywords :  Adal imumab;  Etanercept ; 
Discontinuation; Persistence; Psoriatic arthritis; 
Switch; Treatment patterns
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic, immune-
mediated, inflammatory disease with a wide 
global variation in prevalence, ranging up 
to 420 cases per 100,000 people [1]. Joint 
swelling and pain associated with PsA have a 
substantial negative impact on health-related 
quality of life [2,3]. Patients with PsA experience 
continuing disability, resulting in high rates of 
unemployment and work disability [4,5]. PsA is 
associated with significant socioeconomic and 
healthcare costs, which increase with disease 
severity and age [6–8]. 
Tumor necrosis factor (TNF)-blockers are 
effective for the treatment of many immune-
mediated inflammatory diseases, including 
PsA [9]. Etanercept (Immunex Corporation, 
Thousand Oaks, CA, USA) and adalimumab 
(Abbott Laboratories, North Chicago, IL, 
USA) are the most commonly prescribed TNF-
blockers approved for the treatment of PsA, 
and have been shown to reduce the signs and 
symptoms, inhibit the progression of structural 
damage from active arthritis, and improve the 
physical function of patients with PsA [10–13]. 
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prescription refill. Gaps in therapy of at least
7 days (pauses in therapy) were identified. 
Pauses in therapy were not identified following 
the last prescription fill. Therapy persistence was 
defined as continuous use of index medication 
without gaps in therapy of at least 60 days. 
Patients with a gap in index therapy of at 
least 60 days were classified as discontinuing 
their index TNF-blocker and were further 
classified into one of four mutually exclusive 
groups: (1) discontinued biologic therapy (did 
not receive any other biologic therapy after 
the gap of at least 60 days), (2) restarted index 
therapy (after the gap of at least 60 days), 
(3) switched (started another biologic agent 
after the index biologic), and (4) other (e.g., 
switched to another biologic and then switched 
back to index medication).
Statistical Analysis
Statistical tests of significance for differences 
between etanercept and adalimumab used the 
chi-squared test for categorical variables; t tests 
and analysis of variance (ANOVA) were used for 
normally distributed continuous variables, and 
nonparametric Wilcoxon and Kruskal–Wallis 
tests were used for continuous variables not 
normally distributed.
RESULTS
Patient Characteristics and Initial Dose
Among 346 eligible patients with PsA, 
202 (58.4%) started on therapy with etanercept 
and 144 (41.6%) started therapy with 
adalimumab. Demographic characteristics 
were similar between groups (Table 1). The 
majority of patients (54–56%) were from the 
southern region of the US and most (74–79%) 
received their care from a rheumatologist. 
patients were adults (age 18–64 years) at the time 
of therapy initiation, were continuously enrolled 
in the health plan for at least 6 months before 
and at least 12 months after initiation of therapy, 
and had at least one claim with a diagnosis of 
PsA (ICD-9 696.0) from 6 months before through 
30 days after therapy initiation. Patients were 
excluded from the study if they had a diagnosis 
for which TNF-blockers are often used, including 
rheumatoid arthritis (ICD-9 714.2), juvenile 
idiopathic arthritis (ICD-9 714.3), ankylosing 
spondylitis (ICD-9 720.0), Crohn’s disease (ICD-9 
555.2), ulcerative colitis (ICD-9 556.8), or psoriasis 
(ICD-9 696.1) during the 6 months prior to 
therapy initiation, through disenrollment or end 
of study. Patients with cancer (ICD-9 140.x–239.x) 
or human immunodeficiency virus infection 
(ICD-9 042.x) were also excluded. Diagnosis codes 
in all positions on the medical claim (i.e., primary 
and secondary diagnoses) were used throughout 
the inclusion and exclusion periods. Patients 
could not have had etanercept or adalimumab 
administered in a physician’s office (evidence that 
the patient did not self-administer medications) 
or have a claim for other biologics of interest 
(abatacept, adalimumab, alefacept, anakinra, 
efalizumab, etanercept, golimumab, infliximab, 
rituximab, ustekinumab) during the 6 months 
prior to therapy initiation.
Study Measures
The initial TNF-blocker dose was defined 
as the average weekly dose of the initial 
prescription fill based on the quantity, drug 
strength, and number of days’ supply. Patients 
were categorized according to their initial 
weekly dose of etanercept (50 mg weekly, 
<50 mg weekly, or other) or adalimumab 
(40 mg weekly, 40 mg EOW, or other). Gaps 
in therapy were defined as the time between 
the run-out of a fill until the date of the next 
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The majority of patients started their therapy 
at the dose recommended by the Food and 
Drug Administration. The most common 
comorbidity in both groups was hypertension. 
Of patients starting therapy with etanercept, 
3.0% started at less than 50 mg weekly, 90.6% 
started at 50 mg weekly, and 6.4% started at 
100 mg weekly. Of patients starting therapy 
with adalimumab, 0.7% started at less than 
40 mg EOW, 88.9% started at 40 mg EOW, and 
10.4% started at more than 40 mg weekly.
Therapy Persistence
In the first year of TNF-blocker therapy, similar 
proportions of patients starting on etanercept 
(50%) and patients starting on adalimumab 
(45%) were persistent (no gaps in at least 
60 days) on their index medication (P = 0.37). 
The mean duration of persistence was 
434 days (standard deviation [SD] = 347; 
95% confidence interval [CI] = 385–482) for 
patients on etanercept and 353 days (SD = 298; 






Male sex (%) 56.4 56.9
Age (years, mean ± SD)
Range
45.6 ± 10.9 
18–82
45.0 ± 10.3 
18–76





















































Adv Ther (2012)  29(8):691–697. 695
95% CI = 304–402) for patients on adalimumab 
(P = 0.02).
Pauses in Therapy
Etanercept patients had a significantly greater 
mean number of pauses (4.7; SD = 4.3; 95% CI = 
4.1–5.3) than did adalimumab patients (3.5; SD 
= 3.4; 95% CI = 3.0–4.1; P = 0.004), and a longer 
mean pause length (48.6 days; SD = 95.0; 95% 
CI = 35.4–61.7) than adalimumab patients (29.3 
days; SD = 37.9; 95% CI = 23.0–35.5; P = 0.01).
Treatment Patterns in Discontinued Therapy 
Patients 
Among PsA patients, 125 patients on etanercept 
(61.9%) and 94 patients on adalimumab 
(65.3%) had a gap in index therapy of at least 
60 days (i.e., they discontinued therapy). 
Among patients who discontinued therapy, 
rates of sustained discontinuation of the index 
medication without restart or switch were similar 
between patients who started on etanercept 
(24.8%) and those who started on adalimumab 
(35.1%; P = 0.10) (Fig. 1). Similar percentages of 
patients restarted their index TNF-blocker after 
a gap in therapy of at least 60 days: 46.4% of 
patients on etanercept and 41.5% of patients on 
adalimumab (P = 0.47). Approximately 20% of 
patients who started on etanercept and 19% of 
patients who started on adalimumab switched to 
another biologic to treat their PsA after at least 
a 60-day gap (P = 0.88). The remaining 4.3% of 
patients treated with etanercept and 8.8% of 
patients treated with adalimumab followed an 
alternative treatment pattern after their initial 
discontinuation, such as temporarily switching 
to a different biologic and then switching back 
to the index treatment.
DISCUSSION
The present study evaluated biologic treatment 
patterns among PsA patients; variables measured 
included persistence, pauses in therapy, restarts, 
switches, and discontinuation. Treatment 
patterns were similar for patients who started 
biologic therapy with etanercept and those 
who started therapy with adalimumab for the 
treatment of PsA in this US commercial health 
plan. For both etanercept and adalimumab, the 
majority of patients started at the recommended 
labeled dosing. Approximately 50% of patients 
with PsA were persistent on their index TNF-
blocker for at least 1 year. Both patients receiving 
etanercept and those receiving adalimumab had 
an average of three to four pauses in therapy 
of at least 7 days. The percentage of patients 
with at least a 60-day gap was high (62–65%), 
but of these patients more than 40% restarted 
Fig. 1  Treatment patterns in patients with psoriatic 
arthritis, showing the proportion of patients with at least 
a 60-day gap in index therapy (219 out of a total of 346 
patients in the study) who went on to discontinue all TNF-
blockers, restart index medication, or switch to another 
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their index TNF-blocker and an additional 20% 
switched to another TNF-blocker.
In a study of 566 PsA patients enrolled in 
the BSRBR, 75.5% of patients were persistent 
on their index TNF-blocker at 12 months [14]. 
This rate is higher than the persistence rates 
observed in the present study’s US population 
(50% of patients on etanercept and 45% of 
patients on adalimumab). This difference may 
be attributable to the definition of persistence 
used in each study; gaps in therapy up to 
3 months were allowed in the BSRBR study, to 
accommodate treatment of infections or for elective 
surgery, whereas patients in the present study were 
considered discontinued if they did not restart 
index medication after a 60-day gap [14]. The rates 
of discontinuation without switch or restart were 
similar between the BSRBR study (24.5%) [14] and 
the present study (24.8% of patients on etanercept 
and 35.1% of patients on adalimumab).
The findings of this study may be generalizable 
to PsA patients who receive etanercept or 
adalimumab in US-managed healthcare plans. 
Limitations of the study include those due to 
the nature of claims-based analyses, such as 
the ability of these data to accurately capture 
individual medical history and comorbidities 
that affect treatment decisions and reasons for 
discontinuation. The study population was 
restricted to those patients who had at least 
18 months of continuous enrollment in the 
health plan (6 months before and a minimum of 
12 months after therapy initiation) and started 
either etanercept or adalimumab therapy; this 
group of patients may have a different overall 
health status than the general population of 
PsA patients. This study focused on the biologic 
therapies etanercept and adalimumab and did 
not evaluate other systemic therapies or the 
potential effect of concomitant therapies, such 
as methotrexate, on treatment patterns. This 
study may not be generalizable to other PsA 
populations, such as the entire US population, or 
Medicare, underinsured, or uninsured patients.
The treatment patterns observed in this 
study showed that approximately half of the 
PsA population had a change in therapy within 
the first year of starting a biologic therapy, and 
many of these restarted or switched biologics. 
The reasons for switching are unknown and 
likely include adverse events, lack of efficacy, 
and nonclinical issues such as changes in 
formulary or copay burden. This study showed 
that patients receiving etanercept had a 
longer duration of persistency than those on 
adalimumab in this US commercial health 
plan, although the percentages of patients 
who were persistent on therapy did not vary 
significantly between the two groups. There 
were also more gaps in therapy with etanercept 
(4.7 for etanercept vs. 3.5 for adalimumab) and 
the gaps were longer (49 days for etanercept vs. 
29 days for adalimumab). The additional length 
of therapy may in part be accounted for by the 
gaps and time off therapy. The reasons for the 
differences between adalimumab and etanercept 
could not be determined from the claims data 
used in this analysis. 
CONCLUSION
In this retrospective analysis of real-world 
treatment patterns for etanercept and adalimumab 
in a US commercial health plan, treatment 
patterns were similar for patients receiving 
etanercept and adalimumab. Approximately 
half of PsA patients were persistent on their 
index medication for 12 months and pauses and 
gaps in therapy were common. Of patients who 
discontinued their index medication, more than 
40% restarted their index therapy. Further studies 
to investigate the reasons for and consequences of 
discontinuations, pauses, and gaps in therapy are 
warranted, as minimizing gaps in therapy would 
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be expected to maximize the clinical benefits of 
TNF-blocker therapy in patients with PsA.
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